1. Home
  2. INM vs LEXX Comparison

INM vs LEXX Comparison

Compare INM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.30

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$3.80

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INM
LEXX
Founded
1981
2004
Country
Canada
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.7M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
INM
LEXX
Price
$1.30
$3.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
66.3K
80.6K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
62.68
N/A
EPS
N/A
N/A
Revenue
$4,942,633.00
$705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
7.50
52.05
52 Week Low
$0.58
$0.35
52 Week High
$2.50
$14.37

Technical Indicators

Market Signals
Indicator
INM
LEXX
Relative Strength Index (RSI) 36.87 38.42
Support Level $1.03 $0.62
Resistance Level $1.40 $12.89
Average True Range (ATR) 0.08 1.68
MACD -0.01 -0.95
Stochastic Oscillator 5.97 0.11

Price Performance

Historical Comparison
INM
LEXX

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: